Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients

Published:2012-11-02 Issue:2 Volume:8 Page:280-289
ISSN:1555-9041
Container-title:Clinical Journal of the American Society of Nephrology
language:en
Short-container-title:CJASN

Author:

Wüthrich Rudolf P.,Chonchol Michel,Covic Adrian,Gaillard Sylvain,Chong Edward,Tumlin James A.

Publisher

American Society of Nephrology (ASN)

Subject

Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology

Reference13 articles.

1. Control of Hyperphosphatemia among Patients with ESRD

2. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients

3. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

4. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

5. Kidney Disease Improving Global Outcomes (KDIGO): Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Chapter 3.1: Diagnosis of CKD-MBD: Biochemical abnormalities. Kidney Int Supp 76[Suppl 113]: S22–S49, 2009

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tolerability, safety, and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis;Nephrology Dialysis Transplantation;2024-03-07

2. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study;Nephron;2023-07-20

3. Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study;Nefrología (English Edition);2022-09

4. Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients;Scientific Reports;2022-06-10

5. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia;Expert Opinion on Drug Safety;2021-10-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3